Oral cinnarizine for the treatment of COVID‐19‐associated chilblain‐like lesions: An old drug for a new disease?

During SARS‐CoV‐2 pandemic, an outbreak of chilblain‐like lesions has been developed, even if the relationship with the virus infection is still debated. We report the good results obtained in 12 patients with chilblain lesions and the use of oral cinnarizine, a piperazine derivative with many pharmacological properties among whom antihistaminic and calcium channel blocking activities.

[1]  M. Cutrone,et al.  BNT162b2 mRNA COVID‐19 vaccine‐induced chilblain‐like lesions reinforces the hypothesis of their relationship with SARS‐CoV‐2 , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  M. Cutrone,et al.  Chilblain‐like lesions and COVID‐19: second wave, second outbreak , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  T. Russo,et al.  Chilblain-Like Lesions during COVID-19 Pandemic: The State of the Art , 2021, Life.

[4]  D. Lipsker.  A chilblain epidemic during the COVID-19 pandemic. A sign of natural resistance to SARS-CoV-2? , 2020, Medical Hypotheses.

[5]  V. Piccolo,et al.  Chilblain‐like lesions during the COVID‐19 pandemic: should we really worry? , 2020, International journal of dermatology.

[6]  V. Piccolo,et al.  Acral findings during the COVID-19 outbreak: Chilblain-like lesions should be preferred to acroischemic lesions , 2020, Journal of the American Academy of Dermatology.

[7]  S. Dahan,et al.  Chilblains is a common cutaneous finding during the COVID-19 pandemic: A retrospective nationwide study from France , 2020, Journal of the American Academy of Dermatology.

[8]  A. Bhandari,et al.  Cinnarizine: A Contemporary Review , 2017, Indian Journal of Otolaryngology and Head & Neck Surgery.

[9]  Nadia G. Haress.  Cinnarizine: Comprehensive Profile. , 2015, Profiles of drug substances, excipients, and related methodology.